非类固醇抗炎药物 降低严重烧伤患者凝血病的发生率
Lyndon Huang1, Kassandra Corona1, Kendall Wermine1
1School of Medicine, University of Texas Medical Branch, Galveston, TX 77555, USA.
European burn journal
|November 27, 2024
概括
非类固醇抗炎药物 (NSAIDs) 显著减少严重烧伤患者的凝血病,败血症和死亡率. 早期的NSAID使用在灼伤伤害的急性阶段提供保护性益处.
科学领域:
- 创伤外科 手术 创伤外科
- 药理学 药理学是指药理学的学科.
- 关键护理医学 关键护理医学
背景情况:
- 烧伤引起的凝血病是一种严重的并发症,会影响患者的治疗结果.
- 早期干预策略对于管理严重烧伤至关重要.
- 非类固醇抗炎药物 (NSAIDs) 有潜在的抗炎和止痛特性.
研究的目的:
- 调查早期非类固醇抗炎药物 (NSAID) 给药对燃烧引起的凝血病的影响.
- 评估NSAIDs对严重烧伤患者死亡率和败血症发展的影响.
- 确定NSAID在严重烧伤的急性阶段的保护作用.
主要方法:
- 使用TriNetX研究网络进行的回顾性队列研究.
- 严重烧伤患者 (TBSA> 20%) 在烧伤后的第一个星期内接受NSAIDs的鉴定.
- 在匹配后,统计分析比较NSAID和非NSAID组之间的凝血病,败血症和死亡率.
主要成果:
- 使用NSAID与炎症引起的凝血病的显著减少有关 (17.7%与32.3%,p < 0.0001).
- 接受NSAID治疗的患者的败血症 (p < 0.01) 和死亡率 (p < 0.0001) 显著降低.
- 无 NSAID 组也显示出血小板缩的显著降低 (p < 0.001).
结论:
- 在严重烧伤的患者中,NSAIDs的早期使用显示出显著的保护作用.
- 无 NSAIDs 降低燃烧引起的凝血病,败血症和急性阶段死亡的风险.
- 无抗炎药是一种潜在的治疗选择,可以改善严重烧伤管理的结果.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
623
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
623
01:22Burn Injuries
2.4K
Burn injuries occur when the skin and underlying tissues are damaged due to exposure to heat, electricity, chemicals, radiation, or friction. They can vary in severity, from minor superficial burns to severe deep burns that can be life-threatening.
The damage results in the death of skin cells, which can lead to a massive loss of fluid. Dehydration, electrolyte imbalance, and renal and circulatory failure follow, which can be fatal. Burn patients are treated with intravenous fluids to offset...
The damage results in the death of skin cells, which can lead to a massive loss of fluid. Dehydration, electrolyte imbalance, and renal and circulatory failure follow, which can be fatal. Burn patients are treated with intravenous fluids to offset...
2.4K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
469
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
469
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
5.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.6K
01:05Introduction to Hemostasis
5.7K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
5.7K